Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome
Sponsor: Hospices Civils de Lyon
Summary
This is a randomized controlled, parallel group, open label versus "no treatment" trial which evaluate the efficacy of rhGH on weaning off parenteral nutrition in children with short bowel syndrome.The total follow-up is 14 months; 4 months for each group after randomization; At the end of the first four months: the treated group will be followed within 6 months, the untreated group will receive compassionately rhGH for 4 months and followed-up for 6 months after the end of the treatment period.
Key Details
Gender
All
Age Range
3 Years - 18 Years
Study Type
INTERVENTIONAL
Enrollment
14
Start Date
2006-06
Completion Date
2008-06
Last Updated
2026-05-06
Healthy Volunteers
No
Conditions
Interventions
rhGH
Locations (1)
Alain LACHAUX
Lyon, France